Elevance Health reported strong Q2 results, beating analyst estimates for both adjusted earnings and revenue, and subsequently raised its full-year and fiscal 2026 guidance. This positive performance led to several analyst price target revisions, with two out of three increasing their targets, indicating a generally optimistic outlook.
Elevance Health's Q2 earnings significantly surpassed analyst expectations, with adjusted earnings of $7.45 per share against an estimated $6.21, and revenue of $49.83 billion exceeding the $48.69 billion consensus. This strong performance prompted the company to raise its fiscal 2026 adjusted earnings guidance from at least $26.75 to at least $27 per share, and its operating cash flow forecast to at least $6 billion. The market reacted positively, with shares rising 1.8% in pre-market trading. Analysts, including Baird and Guggenheim, responded by increasing their price targets, reflecting improved sentiment and future expectations for ELV. While Barclays lowered its target slightly, the overall analyst consensus remains positive, suggesting a short-term opportunity for traders on the back of strong fundamentals and a long-term positive outlook for the company.